Back to top
more

Alcon (ALC)

(Delayed Data from NYSE)

$89.64 USD

89.64
710,465

+0.51 (0.57%)

Updated Jun 3, 2024 04:00 PM ET

After-Market: $89.67 +0.03 (0.03%) 7:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch

by Zacks Equity Research

With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.

Alcon (ALC) Surgical Arm Expands, International Growth Slows

by Zacks Equity Research

In Surgical, Alcon (ALC) remains the market leader in presbyopia correcting IOLs on the strength of both PanOptix and Vivity.

Alcon's (ALC) Q4 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.

Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise

by Zacks Equity Research

Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief

by Zacks Equity Research

Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.

Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption

by Zacks Equity Research

Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Here's Why You Should Hold on to Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.

Alcon (ALC) on Track With Successful Global PRECISION1 Rollout

by Zacks Equity Research

Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.

Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption

by Zacks Equity Research

Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.

Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves

by Zacks Equity Research

Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.

Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases

by Zacks Equity Research

Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Strong performance by the Healthcare, AST and Life Sciences segments is driving the top line for STERIS (STE).

Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade

by Zacks Equity Research

Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets

by Zacks Equity Research

QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.

Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance

by Zacks Equity Research

According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.

Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact

by Zacks Equity Research

Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.

NuVasive (NUVA) Announces Two Developments in Cohere TLIF Line

by Zacks Equity Research

According to NuVasive (NUVA), Porous PEEK is a clear differentiator for the company in the market.

Hologic (HOLX) to Expand Surgical Portfolio With Bolder Buyout

by Zacks Equity Research

Hologic's (HOLX) recent acquisition will accelerate its growth and enhance patient outcomes by leveraging significant commercial resources and strong relationships with OB/GYN specialists.

Quest Diagnostics (DGX) Enhances Lab Experience With Facility

by Zacks Equity Research

Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.

Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities

by Zacks Equity Research

Quest Diagnostics' (DGX) efforts to support AHA will boost innovative solutions like the Scholars programs, hypertension control and COVID-19 rapid response.

Medtronic (MDT) Sees Business Recovery Despite Volume Pressure

by Zacks Equity Research

According to Medtronic (MDT), healthcare systems are better prepared as vaccination rates continue to increase.

Here's Why You Should Retain Tandem Diabetes (TNDM) for Now

by Zacks Equity Research

Investors are optimistic about Tandem Diabetes (TNDM) owing to robust international pump shipments and product launches.

Here's Why You Should Add STERIS (STE) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to elevated consumer demand and rebound in procedure volumes and raised 2022 outlook.